3/18
11:20 am
sprb
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect? [Yahoo! Finance]
Medium
Report
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect? [Yahoo! Finance]
3/18
05:17 am
sprb
Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss [Yahoo! Finance]
Medium
Report
Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss [Yahoo! Finance]
3/10
08:43 am
sprb
Spruce Biosciences (SPRB) had its price target lowered by Citizens Jmp from $180.00 to $170.00. They now have a "market outperform" rating on the stock.
Medium
Report
Spruce Biosciences (SPRB) had its price target lowered by Citizens Jmp from $180.00 to $170.00. They now have a "market outperform" rating on the stock.
3/10
08:03 am
sprb
Spruce Biosciences (SPRB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $200.00 price target on the stock.
Medium
Report
Spruce Biosciences (SPRB) had its "buy" rating reaffirmed by HC Wainwright. They now have a $200.00 price target on the stock.
3/9
08:46 am
sprb
Spruce Biosciences GAAP EPS of -$50.83 misses by $29.59 [Seeking Alpha]
Low
Report
Spruce Biosciences GAAP EPS of -$50.83 misses by $29.59 [Seeking Alpha]
3/9
07:35 am
sprb
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]
High
Report
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates [Yahoo! Finance]
3/9
07:05 am
sprb
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
High
Report
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
3/9
07:03 am
sprb
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer [Yahoo! Finance]
High
Report
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer [Yahoo! Finance]
3/9
07:00 am
sprb
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
High
Report
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
3/4
12:34 am
sprb
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway [Yahoo! Finance]
Medium
Report
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway [Yahoo! Finance]
3/2
04:35 pm
sprb
Spruce Biosciences to Present at Upcoming Investor Conferences in March [Yahoo! Finance]
Low
Report
Spruce Biosciences to Present at Upcoming Investor Conferences in March [Yahoo! Finance]
3/2
04:05 pm
sprb
Spruce Biosciences to Present at Upcoming Investor Conferences in March
Low
Report
Spruce Biosciences to Present at Upcoming Investor Conferences in March
2/19
07:07 am
sprb
Spruce Biosciences (NASDAQ:SPRB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Spruce Biosciences (NASDAQ:SPRB) had its "buy" rating reaffirmed by analysts at HC Wainwright.
2/18
07:00 am
sprb
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Medium
Report
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
2/17
04:28 pm
sprb
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Medium
Report
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/17
04:05 pm
sprb
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/5
04:05 pm
sprb
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
Low
Report
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
2/3
08:36 am
sprb
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team [Yahoo! Finance]
Medium
Report
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team [Yahoo! Finance]
2/3
08:00 am
sprb
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
Medium
Report
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
1/28
08:00 am
sprb
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
Medium
Report
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
1/19
01:53 am
sprb
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration [Yahoo! Finance]
Medium
Report
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration [Yahoo! Finance]
1/18
07:02 pm
sprb
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
Medium
Report
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
1/8
08:00 am
sprb
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
Medium
Report
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
12/27
01:05 am
sprb
Spruce Biosciences (NASDAQ:SPRB) was downgraded by analysts at
Wall Stre
Low
Report
Spruce Biosciences (NASDAQ:SPRB) was downgraded by analysts at
Wall Stre